Investors are cautioned that, except as disclosed in the Listing Statement (or other disclosure documents to be prepared by the Parties) to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. There can be no assurance that the Transaction will be completed as proposed or at all. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.Ĭompletion of the Transaction is subject to a number of conditions. None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements. The Company is an unlisted Canadian public company, reporting in the provinces of British Columbia, Alberta and Quebec. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit About the Company Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. The DRS statements are expected to be emailed to all Novamind shareholders no later than December 24, 2020. Novamind shareholders will receive their Common Shares by email in the form of Direct Registration System (" DRS") statements that can be deposited for trading. Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker "NM" on or about January 5, 2021. The Parties will carry on the business of Novamind, a leading mental health company specialized in psychedelic-assisted psychotherapy. (" Novamind", and together with the Company, the " Parties"), the Parties are pleased to announce that they have received conditional approval from the Canadian Securities Exchange (the " CSE") for listing of the common shares of the Company (the " Common Shares") following the completion of the previously announced reverse takeover transaction (the " Transaction") with Novamind. (formerly Hinterland Metals Inc.) (the " Company") and Novamind Ventures Inc. TORONTO, ON / ACCESSWIRE / Decem/ Further to the July 5, 2020, Novemand Novempress releases issued by Novamind Inc. Any failure to comply with this restriction may constitute a violation of U.S. Newswire Services or for dissemination in the United States.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |